Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Masitinib Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AB Science today provides an update on its masitinib platform
    AB Science today provides an update on its masitinib platform

    29 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/29/3017503/0/en/AB-Science-today-provides-an-update-on-its-masitinib-platform.html

    GLOBENEWSWIRE
    29 Jan 2025
    Share Share
    AB Science Updates On Masitinib In Multiple Sclerosis
    AB Science Updates On Masitinib In Multiple Sclerosis

    23 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/23/2951617/0/en/AB-Science-provides-an-update-on-the-development-of-masitinib-in-progressive-forms-of-multiple-sclerosis-post-ECTRIMS-2024.html

    GLOBENEWSWIRE
    23 Sep 2024
    Share Share
    AB Science announces results of Phase 2 study evaluating masitinib in Covid-19
    AB Science announces results of Phase 2 study evaluating masitinib in Covid-19

    08 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/08/2909366/0/en/AB-Science-announces-positive-results-of-its-Phase-2-study-evaluating-masitinib-in-Covid-19.html

    GLOBENEWSWIRE
    08 Jul 2024
    Share Share
    AB Science Updates On Masitinib Application For ALS
    AB Science Updates On Masitinib Application For ALS

    28 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/28/2905749/0/en/AB-Science-provides-an-update-on-the-application-for-conditional-marketing-authorisation-of-masitinib-in-ALS.html

    GLOBENEWSWIRE
    28 Jun 2024
    Share Share
    AB Science Updates On Masitinib Application For ALS Approval
    AB Science Updates On Masitinib Application For ALS Approval

    29 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/29/2890131/0/en/AB-Science-provides-an-update-on-the-application-for-conditional-marketing-authorisation-of-masitinib-in-ALS.html

    GLOBENEWSWIRE
    29 May 2024
    Share Share
    AB Science Masitinib EU Patent To 2036 In Mastocytosis
    AB Science Masitinib EU Patent To 2036 In Mastocytosis

    13 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/13/2880740/0/en/AB-Science-announces-issuance-of-a-European-patent-for-masitinib-in-the-treatment-of-severe-mastocytosis-with-protection-until-2036.html

    GLOBENEWSWIRE
    13 May 2024
    Share Share